Stocktoria
TENAX THERAPEUTICS, INC. TENX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1993-10-28
TENAX THERAPEUTICS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| R&D expense | $32.7M | $12.7M | $3.2M | $5.4M | $25.1M |
| SG&A expense | — | — | — | — | $7.6M |
| Operating income | -$56.4M | -$19.5M | -$8.2M | $11.1M | -$32.7M |
| Interest expense | $0 | $23,000 | $24,000 | $4,443 | $949 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$52.6M | -$17.6M | -$7.7M | $11.0M | -$32.5M |
| EPS (diluted) | $-1.34 | $-1.15 | $-31.04 | — | — |
| Operating cash flow | -$35.8M | -$14.8M | -$5.9M | -$11.4M | -$10.9M |
| Free cash flow | — | — | — | -$11.4M | -$10.9M |
| Cash & equivalents | $97.6M | $94.9M | $9.8M | $2.1M | $5.6M |
| Total assets | $104.2M | $96.7M | $11.7M | $3.4M | $6.0M |
| Total liabilities | $7.2M | $4.7M | $3.6M | $1.9M | $1.7M |
| Shareholders' equity | $97.1M | $92.0M | $8.1M | $1.5M | $4.2M |
Source: SEC EDGAR filings · CIK 0000034956 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.